Navigation Links
ImmunoWELL EBV VCA IgM Test

ProductsImmunoWELL EBV VCA IgM Test
Company GenBio
Item ImmunoWELL EBV VCA IgM Test
Features 
  • ImmunoWELL products use the industry standard microtiter plate format.
  • Optimized to work in both manual and automated testing environments
  • Unused reaction wells can be re-sealed in the pouch using the integral zip-lock.
Description The ImmunoWELL VCA IgM Test is an ELISA method for the qualitative detection of IgM antibody to Epstein-Barr Virus viral capsid antigen (VCA) in human serum. When the VCA IgM test is used in conjunction with other testing such as the EBV nuclear antigen (EBNA-1), VCA IgG, and EBV early antigen tests and/or heterophile tests, the results can serve as an aid in the diagnosis of infectious mononucleosis (IM).
Info GenBio
Customer Service: (858) 592-9300
Web site: http://www.genbio.com

Related medicine products :

1. ImmunoWELL Cardiolipin Antibody (IgG) Test
2. ImmunoWELL Cardiolipin Antibody (IgM) Test
3. ImmunoWELL TPO IgG Quantitative Test
4. ImmunoWELL Thyroglobulin IgG Quantitative Test
5. ImmunoWELL Borrelia (Lyme) Test
6. ImmunoWELL™ Varicella Zoster Virus IgG Test
7. ImmunoWELL EBV VCA IgG Test
8. ImmunoWELL EBNA IgG Test
9. ImmunoWELL EBV EA(D) IgG Test
10. ImmunoWELL Measles (Recombinant) IgG Test
11. ImmunoWELL Mumps Virus IgG Test
Breaking Medicine Technology:Cambridge Scientists Archive 500,000th Crystal Structure 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Covance Inc Invites You to Join the Webcast of Its Second Quarter 2009 Financial Results Conference Call 50805 1Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease 4686 1Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease 4686 2Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease 4686 3Living Medical Textbook 28TM 29 from Projects In Knowledge 28R 29 50802 1Living Medical Textbook 28TM 29 from Projects In Knowledge 28R 29 50802 2Living Medical Textbook 28TM 29 from Projects In Knowledge 28R 29 50802 3